Aristotle Atlantic Partners’s Celgene Corp CELG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-116,987
Closed -$11.6M 102
2019
Q3
$11.6M Buy
116,987
+321
+0.3% +$30.5K 3.35% 9
2019
Q2
$10.8M Sell
116,666
-23,115
-17% -$2.2M 3.14% 10
2019
Q1
$13.2M Sell
139,781
-36,608
-21% -$3.2M 4.01% 7
2018
Q4
$11.3M Sell
176,389
-2,223
-1% -$164K 3.98% 7
2018
Q3
$9.4M Buy
178,612
+2,220
+1% +$196K 5.75% 8
2018
Q2
$14M Buy
176,392
+2,731
+2% +$227K 4.86% 5
2018
Q1
$15.5M Buy
173,661
+174
+0.1% +$16.7K 5.59% 4
2017
Q4
$18.1M Buy
+173,487
New +$19.6M 6.5% 5

Other funds holding CELG

Aristotle Atlantic Partners's CELG Position: Q4 2019 in Review

Aristotle Atlantic Partners sold out of Celgene Corp (CELG) in Q4 2019, closing a stake of 116,987 shares — an estimated $11.6M sold.

Aristotle Atlantic Partners first reported a position in CELG in Q4 2017 and held it in 8 quarters. The position peaked at $18.1M in Q4 2017. 4 funds tracked by Wall St. Rank hold CELG as of Q4 2019.

  • Aristotle Atlantic Partners reported no remaining Celgene Corp position as of Q4 2019 after selling out during the quarter.
  • Aristotle Atlantic Partners sold 116,987 Celgene Corp shares in Q4 2019, an estimated $11.6M.
  • Aristotle Atlantic Partners first reported a position in Celgene Corp in Q4 2017 and held it in 8 quarters.
  • Aristotle Atlantic Partners's Celgene Corp position peaked at $18.1M in Q4 2017.
  • 4 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2019.

Based on Aristotle Atlantic Partners's 13F filing for Q4 2019, filed 13 Feb 2020.